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Acute bacterial skin and skin structure infections (ABSSSIs), or
complicated skin and soft tissue infections (cSSTIs), include a range
of skin and skin structure infections, such as cellulitis/erysipelas,
wound infections, and major cutaneous abscesses. Gram-positive
pathogens, including Staphylococcus aureus (both methicillin-resistant [MRSA] and methicillin-sensitive strains) and Streptococcus
pyogenes, are the most common cause of culture-positive ABSSSI
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[1–3]. Less frequently, other Streptococcus spp., Enterococcus faecalis, or Gram-negative bacteria are implicated.
Acute bacterial skin and skin structure infections are a common
reason for emergency department (ED) visits [4, 5]. Although
guidelines were developed that support outpatient management
of ABSSSIs for appropriate patients [6], hospital admissions in the
United States due to primary diagnosis of skin and skin structure
infections increased from 1.6% in 2005 to 2.0% of patients in 2011
[7]. Furthermore, institutional consistency and guidelines have
not yet been optimized; clinician practices regarding the decision
to provide outpatient or inpatient treatment may vary greatly even
within a single institution [8, 9]. Although hospital admission may
be a strategy that is used in an effort to ensure optimal outcomes,
whether admission improves outcomes requires further investigation [9, 10]. This is especially true because antibiotic stewardship
programs that leverage outpatient treatment pathways and novel
antibiotic therapy may affect treatment strategy, improve patient
outcomes, and reduce costs [11–13].
This study describes the patient, health care facility, and treatment characteristics of those with ABSSSIs and the likelihood
of unplanned 30-day ED visits or readmissions among patients
ABSSSI Readmissions and Unplanned Visits • OFID • 1
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Background. The objective of this study was to characterize treatment of patients with acute bacterial skin and skin structure
infections (ABSSSIs) and describe the association between hospital admission and emergency department (ED) visits or readmissions within 30 days after initial episode of care (IEC).
Methods. This was a retrospective, observational, cohort study of adults with ABSSSI who presented to an ED between July 1,
2012, and June 30, 2013. Patient, health care facility, and treatment characteristics, including unplanned ED visits or readmissions,
were obtained through manual chart review and abstraction. Adjusted logistic regression analysis examined likelihood of all-cause
unplanned ED visits or readmissions between admitted and nonadmitted patients.
Results. Records from 1527 ED visits for ABSSSI from 40 centers were reviewed (admitted, n = 578 [38%]; nonadmitted, n = 949
[62%]). Admitted patients were typically older (mean age, 52.2 years vs 43.0 years), more likely to be morbidly obese (body mass
index > 40 kg/m2; 17.3% vs 9.1%), and had more comorbidities (Charlson Comorbidity Index ≥ 4; 24.4% vs 6.8%) compared with
those not admitted. In the primary analysis, adjusted logistic regression, controlling for comorbidities and severity of illness, demonstrated that there was a similar likelihood of all-cause unplanned ED visits or readmissions between admitted and nonadmitted
patients (odds ratio, 1.03; 95% confidence interval, 0.74–1.43; P = .87).
Conclusions. ABSSSI treatment pathways leveraging outpatient treatment vs hospital admission support similar likelihood of
unplanned 30-day ED visits or readmissions, an important clinical outcome and quality metric at US hospitals. Further research
regarding the decision criteria around hospital admission to avoid potentially unnecessary hospitalizations is warranted.
Keywords. cellulitis; erysipelas; hospital costs; hospitalization; infections; risk factors; skin diseases.

who were admitted vs patients who were not admitted to the
hospital after their initial ED visit. The main purpose of this
study was to evaluate whether treatment location (ie, hospital
admission vs outpatient treatment) was a predictor of unplanned
30-day ED visits or readmissions after initial ABSSSI treatment.
METHODS
Study Design and Study Setting

Study Population

Adult patients aged ≥18 years were included if they had an
ED diagnosis with ≥1 relevant International Classification of
Diseases (ICD)-9 codes: 681.XX (cellulitis and abscess of finger and toe), 682.XX (other cellulitis and abscess), 686.XX
(other local infections of skin and subcutaneous tissue), 958.3X
(posttraumatic wound infection—not elsewhere classified), or
998.5X (postoperative infection—not elsewhere classified) [7].
Patients were excluded if they had a diagnosis of necrotizing
fasciitis (ICD-9 code: 728.86), gas gangrene (040.0), or gangrene (785.6), as these severe infections are not consistent with
the definition of ABSSSI [1]. Patients were excluded if there
was any evidence of fungal infection (alone or in combination
with a bacterial infection) or if the ABSSSI was solely due to
Gram-negative bacteria defined microbiologically. Patients
with known or suspected HIV infection and a CD4 count <200
cells/mm3, or with past or current AIDS-defining condition and
unknown CD4 count, were also excluded.

Patient and Health Care Facility Characteristics

Patient demographics and clinical characteristics that were collected included age, sex, skin infection type, body mass index
(BMI), Charlson Comorbidity Index (CCI), health insurance
type, Systemic Inflammatory Response Syndrome (SIRS) criteria (≥2 criteria: temperature >38°C [100.4°F] or <36°C [96.8°F];
heart rate >90 beats/minute; respiratory rate ≥20 breaths/minute or partial carbon dioxide pressure [PaCO2] ≤32 mmHg;
white blood cell count [WBC] ≥12 000/mm3 or ≤4000/mm3;
and suspected or proven infection), history of ABSSSI within
30 days, hospitalization within 90 days, known history of
MRSA, systemic antibiotic use within 90 days of IEC, and current or past intravenous drug use [IVDU]). Patients were classified as admitted at the IEC if they were admitted as an inpatient
to an intensive care unit (ICU), a unit other than the ICU, or
transferred to another hospital. Patients were classified as not
admitted at the IEC if they were transferred to an observational
bed/unit (from a resource use perspective, these patients are
not considered admitted), discharged to their home, left the ED
against medical advice, transferred to a skilled nursing facility
or long-term care, or if they died before any admission or discharge proceeding.
Health care facility characteristics included geographic
region, hospital organization type (academic vs community), bed capacity, hospital observation unit status (dedicated
observation unit vs interspersed throughout hospital), hospital-owned outpatient infusion center affiliation, integrated
delivery system affiliation, accountable care organization affiliation, and number of full-time equivalents for antibiotic oversight/stewardship in the ED.
Treatment Characteristics

Treatments for ABSSSI received during the IEC and at discharge were described, including whether a lesion culture was
obtained, whether an incision and drainage were performed,
or whether a peripherally inserted central catheter (PICC) was
placed. Antibiotic therapy received during the IEC and at discharge was recorded. Antibiotic therapy was classified as recommended or not recommended (Supplementary Table 1) by 2
investigators (P. Brandon Bookstaver and Timothy C. Jenkins)
based on the Infectious Diseases Society of America (IDSA)
guidelines for empiric skin and soft tissue infection treatment
[14–16]. The duration of antibiotic therapy and the most common therapies at the IEC and at discharge were described [14].

Key Outcome Measures

Unplanned 30-Day ED Visits or Readmissions

Patient, health care facility, and treatment characteristics,
including unplanned ED visits or hospitalizations within 30 days

Patients who had an unplanned visit to the ED or hospitalization for any cause within 30 days of IEC discharge were defined
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This was a retrospective, observational cohort study of adult
patients with ABSSSI who presented to an ED between July 1,
2012, and June 30, 2013, across 40 ED sites in the United States.
Each institution developed a systematic process to identify ≥30
patients meeting study eligibility criteria. Of those patients, at
least 10% were required to have been admitted to the hospital.
The initial episode of care (IEC) was defined as the initial hospital or ED visit up to the point of hospital or ED discharge. As a
result, it is possible that a patient could have spent multiple days
in the ED before discharge.
All collected data were obtained by manual medical chart
review and were de-identified before collation to comply with
current Health Insurance Portability and Accountability Act of
1996 (HIPAA) regulations. Institutional review board approval
was obtained for each site. Patient consent was not required due
to the retrospective nature of the study. The study met the ethical principles of the Declaration of Helsinki.
The study was sponsored by Allergan plc (Dublin, Ireland).
Because most authors were employees of Allergan at the time
of study conduct and analysis, the study sponsor was involved
in the study design, conduct, and analysis and in critical review
and approval of the manuscript.

of the IEC, were obtained through manual chart review and the
abstraction process. Patient-level data were de-identified at the
source and aggregated into a single database for analysis.

as experiencing an unplanned 30-day ED visit or readmission.
In addition to all-cause unplanned 30-day ED visits or readmissions, skin infection–related unplanned 30-day ED visits or
readmissions were assessed.
Data Analysis

RESULTS
Patient Characteristics

In total, records from 1527 patients with ED visits for ABSSSIs
from 40 centers were included in the analysis: 37.9% of patients
(578/1527) were admitted to the hospital at the IEC, whereas
62.1% (949/1527) were not admitted at the IEC (Figure 1).
Among admitted patients, 547/578 (94.6%) were non-ICU
admissions, 29/578 (5.0%) were admitted to the ICU, and 2/578
(0.3%) were transferred to another hospital or destination was
not specified. Of the patients who were not admitted, 894/949
(94.2%) were discharged home, 38/949 (4.0%) were transferred
to an observation bed/unit, 9/949 (0.9%) departed against medical advice, and 8/949 (0.8%) were transferred to a skilled nursing facility or long-term care. Patient demographics and clinical
characteristics are shown in Table 1. Patients who were admitted
were older (mean age, 52.2 years vs 43.0 years), were more likely
to be morbidly obese (BMI > 40 kg/m2; 17.3% vs 9.1%), and had
more comorbidities (CCI ≥4; 24.4% vs 6.8%). The majority of the
overall cohort presented with cellulitis (50.4%) and had evidence
of limited comorbidity (CCI 0 or 1; 52.1% admitted patients vs
84.1% nonadmitted patients). Admitted patients exhibited a
greater severity of infection (as assessed by the presence of SIRS;
32.7% vs 5.6%) than those who were not admitted.

Patients presenting to ED for IEC
n = 1527

Admitted to hospital
n = 578/1527 (37.9%)a

Not admitted to hospital
n = 949/1527 (62.1%)a

Total unplanned ED
visits or readmissions
n = 140/578 (24.2%)b

Total unplanned ED
visits or readmissions
n = 204/949 (21.5%)b

Skin infection–related
ED visits or readmissions
n = 70/578 (12.1%)b

Skin infection–related
ED visits or readmissions
n = 123/949 (13.0%)b

Figure 1. Treatment pathway following the ED visit for the IEC and unplanned 30-day ED visits or readmissions. aAn unplanned ED visit or readmission is an unplanned visit
to the ED or an unplanned hospital admission within 30 days of discharge from the ED or hospital after the IEC. bIndicates percentage of patients from the total subgroup in
the arm of treatment pathway. Abbreviations: ED, emergency department; IEC, initial episode of care.
ABSSSI Readmissions and Unplanned Visits • OFID • 3
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Descriptive statistics were conducted on the patient, health
care facility, and treatment characteristics using counts and
percentages for categorical variables and means and standard
deviations for continuous variables. Both all-cause and skin
infection–related unplanned 30-day ED visits or readmissions
were similarly described.
Unadjusted (ie, univariate) and multivariate logistic regression with adjustment for confounding variables were used to
estimate the likelihood of both all-cause and skin infection–
related unplanned 30-day ED visits or readmissions comparing
patients who were admitted and those who were not admitted
to the hospital. In accordance with causal inference methodology, all variables chosen for logistic regression models occurred
before the decision to admit or not admit was expected to be
made. The outcome for all-cause unplanned 30-day ED visits
or readmissions was used as our primary analysis, as it has been
assessed previously as an important clinical outcome and part
of hospital quality assessment, whereas the outcome for skin
infection–related unplanned 30-day ED visits or readmissions
was used as a secondary analysis. For the primary and secondary analyses, variables were selected for adjustment using
stepwise logistic regression (Model 1); additional variables were
selected to include a second model based on clinical and epidemiologic rationale (Model 2). For the initial stepwise logistic
regression (Model 1), variables that met the threshold (P ≤ .30)
were utilized based on univariate analyses. Forward stepwise

selection determined the final models. The primary predictor
variable (admission status after the IEC) was forced into the
stepwise logistic regression analysis for the final model.
Missing data were not imputed; thus, analyses were undertaken using available data only. Statistical significance was
defined as P < .05. All analyses were conducted using SAS statistical software (SAS, version 9.3; SAS Institute, Cary, NC).

Table 1.

Patient and Treatment Characteristics Stratified by Admission Status
Admitted (n = 578; 37.9%)

Not Admitted (n = 949; 62.1%)

Total (n = 1527)

Patient characteristic
Mean (±SD) age,a y

52.2 (±17)

43.0 (±17)

46.5 (±18)

315 (54.5)

506 (53.3)

821 (53.8)

Cellulitis

332 (57.4)

437 (46.1)

769 (50.4)

Major abscess

160 (27.6)

407 (42.9)

567 (37.1)

92 (9.7)

173 (11.3)

Sex, n (%)
Male
Skin infection type,a,b n (%)

Surgical site infection or traumatic wound

81 (14.0)

BMI,a,b n (%)
283 (49.0)

423 (44.6)

706 (46.2)

30–40 kg/m2

173 (29.9)

286 (30.1)

459 (30.1)

>40 kg/m2

100 (17.3)

86 (9.1)

186 (12.2)

0

174 (30.1)

650 (68.5)

824 (54.0)

1

127 (22.0)

148 (15.6)

275 (18.0)

2

62 (10.7)

74 (7.8)

136 (8.9)

3

74 (12.8)

12 (1.3)

86 (5.6)

141 (24.4)

65 (6.8)

206 (13.5)

CCI score,a n (%)

4+
Health insurance type,a,b n (%)
Commercial

164 (28.4)

256 (27.0)

420 (27.5)

Medicaid

84 (14.5)

163 (17.2)

247 (16.2)

Medicare

126 (21.8)

93 (9.8)

219 (14.3)

Self-pay

103 (17.8)

282 (29.7)

385 (25.2)

Othersc

80 (13.8)

98 (10.3)

178 (11.7)

189 (32.7)

53 (5.6)

242 (15.9)

History of ABSSSI within 30 d before IEC,a,b n (%)

137 (23.7)

103 (10.9)

240 (15.7)

Hospitalization within 90 d before IEC,a,b n (%)

169 (29.2)

99 (10.4)

268 (17.6)

Met initial SIRS criteria,a,b,d n (%)

Known history of MRSA, n (%)a,b

91 (15.7)

Systemic antibiotic use within 90 d before admission,a,b n (%)

238 (41.2)

Current/past IVDU,a,b n (%)

73 (12.6)

78 (8.2)

169 (11.1)

194 (20.4)

432 (28.3)

57 (6.0)

130 (8.5)

Treatment characteristic
Lesion culture obtained,a,b,e n (%)

283 (49.0)

187 (19.7)

470 (30.8)

Gram-positive culturef

198/283 (70.0)

136/187 (72.7)

334/470 (71.1)

MRSAg

108/198 (54.6)

64/136 (47.1)

172/334 (51.5)

204 (35.3)

362 (38.2)

566 (37.1)

96 (16.6)

6 (0.6)

102 (6.7)

Incision and drainage performed on abscess,a n (%)
PICC insertion,a,b n (%)
Antibiotic therapy at IEC
Antibiotic therapy at IEC,a n (%)

568 (98.3)

451 (47.5)

1019 (66.7)

205 (36.1)

355 (77.7)

560 (55.0)

Receipt of guideline-recommended antibiotic therapy during IEC,h,i n (%)
IDSA only
Non-IDSA only

50 (8.8)

55 (12.2)

105 (10.3)

313 (55.1)

41 (9.1)

354 (34.7)

476 (82.4)

848 (89.4)

1324 (86.7)

IDSA only

301 (63.2)

780 (92.0)

1081 (81.7)

Non-IDSA only

116 (24.4)

47 (5.5)

163 (12.3)

59 (12.4)

21 (2.5)

80 (6.0)

Both IDSA and non-IDSAj
Antibiotic therapy at discharge
Antibiotic therapy at discharge,a n (%)
Receipt of guideline-recommended antibiotic therapy at discharge,h,i n (%)

Both IDSA and non-IDSAj

Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; BMI, body mass index; CCI, Charlson Comorbidity Index; ED, emergency department; IDSA, Infectious Diseases
Society of America; IEC, initial episode of care; IVDU, intravenous drug use; MRSA, methicillin-resistant Staphylococcus aureus; PICC, peripherally inserted central catheter; SIRS, systemic
inflammatory response syndrome.
a

Statistically significant difference between those admitted and those not admitted after the initial visit to the ED (P < .05).

b

Data not available for all patients; percentage was calculated using total patients in that category (ie, admitted, not admitted, or total) as the denominator.

c

Includes those with ≥2 insurance types and those with Tricare.

d

Patients not admitted were not given a full set of vital signs and/or laboratory tests.

e

Infections solely due to Gram-negative bacteria were excluded (applies to whole analysis, per exclusion criteria in the “Methods”).

f

The percentage of patients was calculated from those patients for whom a lesion culture was obtained.

g

The percentage of patients was calculated from those patients for whom a Gram-positive culture was obtained.

h

The percentage of patients was calculated from those patients given antibiotic treatment.

i

Statistical analysis testing was not performed for this variable.

j

Includes patients whose antibiotic was recorded as an antifungal or “other” during the IEC and at discharge.
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<30 kg/m2

Health Care Facility Characteristics

Included patients were primarily from facilities located in
the South (43.4% of patients) or Midwest (27.8% of patients)
geographic regions of the United States, a majority of which
were academic medical centers (66.0% of patients) (Table 2;
Supplementary Figure 1). Participating centers from the
Midwest or Northeast regions of the United States and hospitals
affiliated with an Integrated Delivery Network or Accountable
Care Organization included more admitted patients in the
study than other centers. Patients were less likely to be admitted
if they presented at an ED with antibiotic oversight/stewardship
activities (42% vs 49%).
Treatment Characteristics

Table 2.  Health Care Facility Characteristics Stratified by Admission Status
Admitted
(n = 578; 37.9%), n (%)

Not Admitted
(n = 949; 62.1%), n (%)

Total
(n = 1527), n (%)

Midwest

209 (36.2)

216 (22.8)

425 (27.8)

Northeast

94 (16.3)

84 (8.9)

178 (11.7)

South

204 (35.3)

458 (48.3)

662 (43.4)

West

71 (12.3)

191 (20.1)

262 (17.2)

Health Care Facility Characteristic
Geographic regiona

Hospital/organization type
Academic medical center

396 (68.5)

611 (64.4)

1007 (66.0)

Community

182 (31.5)

338 (35.6)

520 (34.1)

<250

21 (3.6)

55 (5.8)

76 (4.9)

250–399

37 (6.4)

83 (8.8)

120 (7.9)

400–749

346 (59.9)

572 (60.3)

918 (60.1)

≥750

174 (30.1)

239 (25.2)

413 (27.1)

Dedicated observation unit

345 (59.7)

473 (49.8)

818 (53.6)

Interspersed throughout hospital

176 (30.5)

357 (37.6)

533 (34.9)

Yes

444 (76.8)

667 (70.3)

1111 (72.8)

No

108 (18.7)

250 (26.3)

358 (23.4)

Yes

271 (46.9)

338 (35.6)

609 (39.9)

No

100 (17.3)

232 (24.5)

332 (21.7)

Bed capacity, No. of bedsa

Hospital observation unit statusa,b

Hospital-owned outpatient infusion center affiliationa,b

Integrated delivery system affiliationa,b

Accountable care organization affiliationa,b
Yes

394 (68.2)

516 (54.4)

910 (59.6)

No

73 (12.6)

273 (28.8)

346 (22.7)

Yes

245 (42.4)

467 (49.2)

712 (46.6)

No

319 (55.2)

468 (49.3)

787 (51.5)

Antibiotic oversight/stewardship activities in the EDa,b

No. of FTEs for antibiotic oversighta,b
0

17 (2.9)

42 (4.4)

59 (3.9)

>0–1

172 (29.8)

431 (45.4)

603 (39.5)

>1–2

174 (30.1)

222 (23.4)

396 (25.9)

>2–3

66 (11.4)

87 (9.2)

153 (10.0)

>3–4

36 (6.2)

9 (0.95)

45 (2.9)

Abbreviations: ED, emergency department; IEC, initial episode of care; FTE, full-time equivalent.
a

Statistically significant difference between those admitted and those not admitted after the initial visit to the ED (P < .05).

b

Data on facility characteristics were not available for all patients.
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Mean (±SD) time spent in the ED was 0.3 ± 2.5 days (7.6 ± 59.7
hours); admitted patients had a mean (±SD) length of hospital

stay of 5.5 ± 7.3 days (132 ± 175 hours). Treatment characteristics were stratified by admission status and are shown in
Table 1. Admitted patients were significantly more likely to have
a culture obtained from a lesion during the IEC when compared with patients who were not admitted (49.0% [283/578]
vs 19.7% [187/949]). Admitted patients were significantly
more likely to either have a PICC line placed (16.6% vs 0.6%;
P < .05) or be given antibiotic therapy during the IEC (98.3% vs
47.5%; P < .05) compared with nonadmitted patients. Of those
patients, a significantly greater percentage of admitted patients
received non-IDSA-recommended antibiotic therapy in conjunction with empirical IDSA-recommended antibiotic therapy
at the IEC when compared with patients who were not admitted
(55.1% vs 9.1%; P < .05). There was no significant difference
in the percentage of patients that received antibiotic therapy at

Unplanned 30-Day ED Visits or Readmissions

The proportion of patients experiencing all-cause unplanned
ED visits or readmissions to the ED or hospital within 30 days
was similar for admitted vs nonadmitted patients (24.2%
[140/578] vs 21.5% [204/949]) and for patients experiencing
skin infection–related unplanned ED visits or readmissions
(12.1% [70/578] vs 13.0% [123/949]) (Figure 1).

40

At IEC
At discharge
Total duration

Mean duration of antibiotic therapy (SD), d

35
30
25
20
15
10
5
0

Admitted

Not admitted

Total

Figure 2. Duration of antibiotic treatment. Abbreviation: IEC, initial episode of
care.
6 • OFID • Bookstaver et al

All-Cause Unplanned ED Revisits or Readmissions

For the primary analysis (Figure 3), unadjusted logistic regression demonstrated that there was similar likelihood of all-cause
unplanned 30-day ED visits or readmissions between admitted
and nonadmitted patients (odds ratio [OR], 1.17; 95% confidence interval [CI], 0.91–1.49; P = .22). For the adjusted logistic
regression for the primary analysis using Model 1 and adjusted
for covariates* (described in Supplementary Table 3), admission
status at the IEC was not significantly associated with all-cause
unplanned 30-day ED visits or readmissions (OR, 1.03; 95%
CI, 0.74–1.43; P = .87). Admission status at the IEC was also
not significantly associated with all-cause unplanned ED visits
or readmissions (OR, 1.02; 95% CI, 0.46–2.22; P = .97) using
Model 2, which was adjusted for additional clinically relevant
covariates† (described in Supplementary Table 3).
*Model 1 covariates: admission status at the IEC; BMI;
hospitalization within 90 days before this admission;
known history of MRSA, including colonization; hospital
type (community, academic medical center); accountable
care organization affiliation.
†
Model 2 was adjusted for the covariates in Model 1, along
with additional clinically relevant covariates: age; health
insurance type; sex; geographical location; CCI; current/
past IV drug use; history of ABSSSI within 30 days; systemic antibiotic use within 90 days before this admission;
met initial SIRS criteria; infection type; patient disposition; hospital-owned outpatient facility; number of fulltime equivalents for antibiotic oversight; bed capacity;
incision and drainage performed on abscess; receipt of
antibiotic therapy; pathogen was cultured.
Skin Infection–Related Unplanned ED Revisits or Readmissions

Similar results were supported for the secondary analysis
assessing the likelihood of skin infection–related unplanned
30-day ED visits or readmissions (OR, 0.93; 95% CI, 0.68–1.27;
P = .63) (Figure 3). For the adjusted logistic regression for the
secondary analysis, admission status was not statistically associated with skin infection–related unplanned 30-day ED visits
or readmissions (OR, 0.52; 95% CI, 0.25–1.12; P = .10) using
Model 1 adjusted for covariates‡ (described in Supplementary
Table 4). However, after adjusting for additional clinically relevant covariates (Model 2),§ results supported a decreased likelihood of skin infection–related 30-day ED visits or readmissions
among admitted vs nonadmitted patients (OR, 0.36; 95% CI,
0.13–0.96; P = .04). Among clinically relevant covariates, none
were individually found to be significant; the combination of
covariates likely drove significance, rather than 1 covariate.
‡

Model 1 covariates: admission status at the IEC; BMI;
CCI; history of ABSSSI within 30 days; known history of
MRSA, including colonization; met initial SIRS criteria;
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discharge between admitted and nonadmitted patients (82.4%
vs 89.4%). The majority of both admitted and nonadmitted
patients received IDSA-recommended antibiotic therapy at
discharge, without concomitant antibiotic therapy that is not
recommended by the IDSA (63.2% vs 92.0%, respectively). The
most common antibiotic treatments administered to patients
at the IEC and discharge are shown in Supplementary Table 2.
Admitted patients received intravenous (IV) vancomycin most
commonly at the IEC and oral trimethoprim/sulfamethoxazole
at discharge; nonadmitted patients most commonly received
oral trimethoprim/sulfamethoxazole at the IEC and discharge.
Of note, admitted patients were more likely to have had a history of ABSSSI within 30 days before the IEC (23.7% vs 10.9%),
hospitalization within 90 days before the IEC (29.2% vs 10.4%),
and a history of MRSA (15.7% vs 8.2%).
The mean (±SD) durations of antibiotic therapy during the
IECs of admitted and nonadmitted patients were 5.8 ± 4.8 days
and 2.0 ± 2.7 days, respectively (P < .05) (Figure 2). The mean
(±SD) durations of antibiotic therapy at discharge of admitted and nonadmitted patients were 13.8 ± 15.4 days and
10.6 ± 4.7 days, respectively (P < .05) (Figure 2). The mean
(±SD) total duration of antibiotic therapy, including both IEC
and discharge antibiotics, was significantly longer for those who
were admitted vs those who were not admitted (19.4 ± 16.9 days
vs 12.8 ± 5.5 days; P < .05) (Figure 2).

All-cause unplanned ED visits or readmissions
Unadjusted analysis
Model 1a
Model 2b
Skin infection–related unplanned ED visits or readmissions
Unadjusted analysis
Model 1a
Model 2b
1

10
Favors discharge from ED
or observation unit

Analysis

OR (95% CI)

P Value

All-cause unplanned ED visits or readmissions
Unadjusted analysis
Model 1: Stepwise logistic regression
Model 2: Addition of clinically relevant variables to Model 1
Skin infection–related unplanned ED visits or readmissions

1.17 (0.91–1.49)
1.03 (0.74–1.43)
1.02 (0.46–2.22)

.22
.87
.97

Unadjusted analysis
Model 1: Stepwise logistic regression
Model 2: Addition of clinically relevant variables to Model 1

0.93 (0.68–1.27)
0.52 (0.25–1.12)
0.36 (0.13–0.96)

.63
.10
.04

Figure 3. Logistic regression models: likelihood of all-cause and skin infection–related unplanned 30-day ED visit or readmission. aModel 1 was the stepwise logistical
regression analysis and included the covariates listed in Supplementary Tables 3 and 4 under Model 1. bModel 2 included the addition of clinically relevant variables and
included the covariates listed in Supplementary Tables 3 and 4 under Model 2. Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; CI, confidence interval;
ED, emergency department; OR, odds ratio.

infection type; hospital geographical location; accountable
care organization affiliation; patient disposition; incision
and drainage performed on abscess.
§
Model 2 was adjusted for the covariates in Model 1, along
with additional clinically relevant covariates: age; health
insurance type; sex; current/past IV drug use; hospitalization within 90 days before this admission; systemic
antibiotic use within 90 days before this admission; hospital type (community, academic medical center); hospital-owned outpatient facility; number of full-time
equivalents for antibiotic oversight; bed capacity; receipt
of antibiotic therapy; pathogen was cultured.
DISCUSSION

Our results support a similar likelihood of unplanned 30-day
ED visits or readmissions among patients admitted to the hospital for ABSSSI treatment vs patients who received outpatient
treatment, after controlling for patient characteristics and
severity of illness. It is the largest observational study to date
in an ABSSSI patient population presenting to EDs, describing

ABSSSI treatment and clinical outcomes for 1527 patients across
40 US EDs. Because we found similar outcomes among admitted vs nonadmitted patients, our results highlight the need for
improved transitions of care to the outpatient setting to prevent
unnecessary or prolonged inpatient care.
The current treatment paradigm for ABSSSI has included
routine hospital admission for the purpose of delivering IV
antibiotic therapy for patients, as no standard criteria have been
developed to assist clinicians with the decision of who should
be admitted for advanced care [17]. Hospital admission may be
required to provide appropriate care for ABSSSI patients with
septic shock, complicating comorbid conditions, or those at risk
of acute deterioration. However, unnecessary hospitalizations
place patients at increased risk for adverse events and hospital-acquired infections, are economically burdensome, and may
not be associated with optimal outcomes [3, 18]. In addition,
hospital readmissions have come under the spotlight as critical
measures in hospital outcomes and are tied to hospital reimbursement [11, 19].
Our primary results support that hospital admission, compared with discharge from the ED, may not affect the likelihood
ABSSSI Readmissions and Unplanned Visits • OFID • 7
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through manual review of medical records, where the process
may have imparted subjectivity or misclassification of ABSSSI.
The primary analysis was completed using available data;
missing information was not imputed. In our comparison of
unplanned 30-day ED visits or readmissions with the primary
predictor variable of admission status, we controlled for multiple
clinical variables in our model but did not perform a propensity
score–matched analysis. Despite adjusting for many confounding variables, there may be residual confounding because
admitted and nonadmitted patients likely have additional clinically important differences not captured in this study. Patients
who died also could not be included for an unplanned 30-day
ED visit or readmission. However, because the number was low
(n = 2; <1%), those patients were not excluded from the overall
calculations, which was not expected to substantially affect the
results. Another limitation was that patients may have visited
a different ED or hospital that was not captured in our data
set. Although we cannot determine the number of patients for
whom this circumstance would apply, the Healthcare Cost and
Utilization Project [29] has estimated the all-cause readmission
across US hospitals to be 11.2% [29]. Because the percentage
of readmission in this study was 22% for admitted patients and
24% for patients not admitted, we do not believe that this limitation severely affected our study. Furthermore, the percentage
of readmission in this study was similar to previously reported
estimates of 30-day readmissions among patients presenting to
the ED with a skin and soft tissue infection [30]. Because of
the study design, we were unable to determine causality regarding why certain groups of hospitals (centers from the Midwest
and Northeast regions of the United States and hospitals affiliated with an Integrated Delivery Network or Accountable Care
Organization) included more admitted patients in the study
than other centers or why patients were less likely to be admitted if they presented at an ED with antibiotic oversight/stewardship activities.
CONCLUSIONS

Acute bacterial skin and skin structure infection treatment
pathways leveraging outpatient treatment vs hospital admission
support similar likelihood of unplanned 30-day ED visits or
readmissions, an important clinical outcome and quality metric
at US hospitals. Further research regarding the decision criteria
around hospital admission, as well as implementation of antibiotic stewardship programs to facilitate transitions of care, is
warranted to avoid potentially unnecessary or prolonged hospital stays.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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of all-cause unplanned 30-day ED visits or readmissions, an
important clinical outcome and quality metric for US hospitals.
These study results may help to reassure clinicians that outpatient management for ABSSSI does not necessarily result in a
higher likelihood of follow-up care within 30 days of the initial
ED presentation. Focusing on identifying the appropriate criteria for hospital admissions and integrating these criteria into care
pathways should reduce or prevent readmissions. However, further research is warranted, specifically for skin infection–related
ED visits or readmissions, to identify significant predictors of
follow-up care. In 1 of the 4 regression models, patients who
were admitted were significantly less likely to receive skin infection–related follow-up care. Although the other 3 models were
not significant in this comparison, these results further support
the opportunity to improve outpatient care pathways in addition
to identifying appropriate criteria for hospital admission criteria.
Improving antibiotic stewardship practices in the ED to
optimize antibiotic therapy and assist in transitions of care
is important. The substantial amount of non–IDSA guideline–concordant antibiotic therapy in the admitted group
and the extended duration of antibiotic therapy in both the
admitted and nonadmitted populations highlight the need for
ongoing antibiotic stewardship among patients with ABSSSI.
Augmenting hospital- and ED-based antibiotic stewardship
programs or the development and integration of care process models would be 2 methods to reduce unnecessarily
broad-spectrum antibiotic use and total duration of therapy [20, 21]. Antibiotic stewardship comprises “coordinated
intervention programs” designed to improve and measure
the appropriate use of antibiotic agents by promoting empiric
selection of the optimal antibiotic drug regimen (eg, dosing,
duration of therapy, and route of administration) [22]. These
programs have been shown to reduce inappropriate antibiotic use, conserve resources, optimize treatment duration,
decrease treatment-related adverse events, and improve the
rates of antibiotic susceptibilities to targeted antibiotics [9,
23–25]. Failure to use antibiotics that are guideline-recommended or use of inappropriate antibiotics, such as the use
of broad-spectrum antibiotics for most cases of ABSSSI, is
associated with increasing drug resistance, adverse events,
and other unintended consequences including Clostridium
difficile infection [26, 27]. Although these programs have primarily been used in the inpatient setting, antibiotic stewardship programs also play a role in EDs [23, 24]. Furthermore,
novel antibiotic therapies such as long-acting parenteral antibiotics may offer an alternative outpatient therapy in patients
where complicating factors do not necessitate hospitalization
yet require IV therapy. Long-acting therapy could reduce traditional institutional barriers to coordinating outpatient treatment, facilitating improved stewardship practices [20, 21, 28].
This study is not without limitations. The lack of randomization may have contributed to selection bias. Data were collected
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